KPV
Also called Lys-Pro-Val
What to know about KPV
KPV is the three-amino-acid C-terminal fragment of alpha-melanocyte-stimulating hormone. Most evidence comes from cell systems and mouse intestinal-inflammation models.
- How it may work
- A key study found uptake through the PepT1 transporter and lower NF-kappa-B-linked inflammatory signalling in cell and mouse experiments.
- What research found
- The best-known paper combined cultured cells with mouse colitis models. FDA reports finding no human exposure data for compounded KPV products.
- What is not settled
- Human absorption, dose-response, immune reactions, and long-term safety remain undefined. Product route and purity add separate uncertainty.
- Research and product status
- KPV is not a licensed U.S. medicine, and the evidence base does not support treating mouse results as human outcomes.
Research reference
- Research amount range
- 200–500 mcg per administration — not a starting amount
- Reference frequency
- Every day — catalogue input, not a personal schedule
- Evidence route
- No human administration route established by this catalogue's evidence tier.
- Model accumulation timescale
- ~3 hours — about five half-lives with regular repeated exposure; not time to a result
- Storage
- Storage and in-use limits depend on the exact formulation and packaging. A compound name alone cannot establish temperature, diluent, or shelf life. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
When results may show
- When change was measured
- The best-known KPV paper used cultured cells and mouse intestinal models. FDA's review found no human exposure data, so a human onset measured in days or weeks cannot be stated.
- When to assess
- There is no human trial endpoint or reassessment week to copy into a protocol. Animal inflammatory-marker timing cannot be translated into a personal symptom timeline.
- Conditions and limitations
- No reliable human evidence establishes an effective route, meal timing, injection location, or required companion compound. Product identity and absorption are unresolved variables.
- When to stop
- No validated target, course length, maintenance phase, or quit rule exists. Continuing because an expected gut or skin result has not appeared would add exposure without human evidence.
Sources: PepT1 and KPV study · FDA compounding-risk review
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Combination evidence and cautions
What is known and unknown about KPV alongside other compounds or medicines.
Key properties
- Formula
- C16H30N4O4
- Mol. weight
- 342.43 Da
- CAS
- 67727-97-3
- PubChem CID
- 125672
Sequence (one-letter)
KPV
External references
A tripeptide cleared quickly by serum peptidases; human PK is thin, and most work is rodent or topical.
Evidence is preclinical; no human study fixes an amount or schedule, so no schedule table is shown.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 3hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- α-MSH / KPV anti-inflammatory literatureMostly rodent and cell models; human injectable amounts are extrapolated.